title: [Assessment of the effectiveness of using low molecular weight heparin in the prophylaxis of venous thrombo-embolic diseases in obstetrics].
abstract: OBJECTIVE
  Assessment of the effectiveness of using low molecular weight heparin in the prophylaxis of venous thrombo-embolic diseases in pregnant women, parturients and puerperants.
  
  
  METHODS
  14,106 female patients were retrospectively analysed in the period between 1990-1999. The patients were divided into 4 groups: I--142 pregnant patients with crural varices, II--10 pregnant patients who had suffered from deep venous thrombosis, III--5 patients with implanted artificial cardiac valves, IV--13,949 patients without any risk factors. In the patients in groups I-III low molecular weight heparin was used prophylactically.
  
  
  RESULTS
  In the studied groups no cases of pulmonary embolism were observed. Superficial venous thrombosis occurred in 10 women (3 in group I and 7 in group IV). Deep venous thrombosis occurred in 5 patients (2 in group I and 3 in group IV). In patients who received low molecular weight heparin over a long period of time, no excessive bleeding during delivery was observed. Other complications in the form of osteoporosis and thrombocytopenia were also not observed.
  
  
  CONCLUSIONS
  1. Administering of low molecular weight heparin during pregnancy, labour and puerperium has no influence on the increase of maternal et fetal complications. 2. Administering of low molecular weight heparin in pregnant women, in labour and in puerperium with increase risk of thrombo-embolic disease allows to avoid pulmonary arteries embolism. 3. Pregnant women and women in puerperium with increased risk of venous thrombo-embolic disease should be under control of experienced obstetrician in cooperation with vascular surgeon and hematologist.
authors.affiliation: Kliniki Rozrodczości i Połoznictwa AM we Wrocławiu.
authors.forename: M
authors.initials: M
authors.lastname: Tomiałowicz
authors.forename: J
authors.initials: J
authors.lastname: Florjański
authors.forename: M
authors.initials: M
authors.lastname: Zimmer
authors.forename: J
authors.initials: J
authors.lastname: Pajak
authors.forename: A
authors.initials: A
authors.lastname: Kłósek
mesh_terms: D000328:Adult; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D011247:Pregnancy; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013924:Thrombophlebitis / Q000175:diagnosis* / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight